Should routine HPV vaccination programs include males 25–29 years? A systematic review and global meta-analysis
This study demonstrates that extending HPV vaccination to males aged 25-29 years provides both individual and population-level benefits, particularly in settings with suboptimal female coverage. These findings support the inclusion of this demographic in vaccination programs and suggest that revising current age-restrictive policies could contribute to global efforts to eliminate HPV-related diseases. Future research should focus on real-world data to further strengthen the evidence base.
Authors
- Shunhong Zhang (ORCID: https://orcid.org/0000-0003-2120-4574)
- Guangyue Liu (ORCID: https://orcid.org/0000-0002-7590-0412)
- Lin-Yong Zhao (ORCID: https://orcid.org/0000-0003-0884-4657)
- Chenchen Luo
- Shubo Wan (ORCID: https://orcid.org/0000-0001-7487-207X)
- Saidi Hu (ORCID: https://orcid.org/0000-0003-4849-6829)
- Luzimery dos Ramos da Conceição
- Marinela da Costa Encarnação
Institutions
- Sichuan University (CN)
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- West China Hospital of Sichuan University (CN)
- Centro Nacional de Endemias (ST)
- Panzhihua Central Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s12967-025-07384-4
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35